Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Personalis to Announce Second Quarter 2023 Financial Results


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and Twitter.


These press releases may also interest you

at 13:00
"I'm a Registered Nurse, and I thought there should be a new under bed pad to absorb urine and keep it away from the patient's skin," said an inventor, from Rosedale, N.Y., "so I invented the HUNTER PAD. My design would also provide a cushion for...

at 12:50
ARCpoint Inc. (the "Company" or "ARCpoint") is pleased to announce that it intends to complete a non-brokered private placement to raise gross proceeds of up to C$1,500,000, (the "Offering") through the sale of up to 20,000,000, subordinate voting...

at 12:09
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies, with the goal of achieving functional cure for chronic hepatitis B...

at 12:05
The "Stem Cell Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of 162 stem cell deals announced since 2016 including financial terms where...

at 11:40
Neuranics, a deep tech startup headquartered in Glasgow, proudly announces its award for Deep Tech Investment of the Year at the UK Angel Investment Awards held on Wednesday night at a glittering ceremony in the Science Museum London. This award...

at 11:25
The "Asia-Pacific Clinical Biomarkers Market - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach...



News published on and distributed by: